Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07815080
Recruiting Observational

Femoral Component TKA: Extramedullary vs Conventional Intramedullary Guide

NCT07815080 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-10-15
Last updated
2026-09-11

Condition(s) studied

Total Knee Replacement

Study summary

The study wants to evaluate the performance of this EM guide in comparison to a traditional IM guide.

75 patients will be included in the extramedullary group (to be compared with a corresponding previous group of 75 patients treated with intramedullary guide).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female ≥ 18 years old * Indication to primary TKA, for any diagnosis operated with EM or IM guides * Signature of the informed consent (only for prospective cohort) * Been operated upon between January 2021 and September 2025 (only for retrospective cohort) Exclusion Criteria: * Revision surgery of knee arthroplasty * Patients with malignant diseases (at the time of surgery) * Patients with proven or suspect infections (at the time of surgery) * Pregnancy end/or lactating (auto declaration) * Patient with known allergy to the specific metallic components of the prosthesis (at the time of surgery)

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Istituto Clinico San Siro Milan Italy Completed
IRCCS Ospedale Galeazzi-Sant'Ambrogio [coordinator] Milan Italy Recruiting
Ospedale Cottolengo Torino Italy Completed

More I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio trials in Italy

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07815080 on ClinicalTrials.gov ↗ ← All trials in Italy